



Office of Research Integrity

US Department of Health and Human Services

— HOME — ABOUT ORI — PRIVACY — FOIA — SITE MAP — CONTACT ORI —

Search ORI

Sections

- Assurance
- Conferences
- Handling Misconduct
- International
- Policies / Regulations
- Publications
- RCR Education
- Research
- RIOs

Newsletter

Latest Newsletter (PDF)
June 2007



Past Issues...

Annual Report

ORI Annual Report 2006
PDF format



Past Reports...

Graduate RCR

Graduate Education for RCR

Case Summary - Joy Bryant

[Federal Register: June 25, 2007 (Volume 72, Number 121)]

[Notices]

[Page 34689]

From the Federal Register Online via GPO Access

[wais.access.gpo.gov] [DOCID:fr25jn07-69]

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Office of the Secretary

Findings of Scientific Misconduct

ACTION: Notice.

SUMMARY: Notice is hereby given that the Office of Research Integrity (ORI) and the Assistant Secretary for Research Integrity (ASRI) have taken the following final action in the following case:

Joy Bryant, University of Oklahoma Health Sciences Center: Based on the report of an investigation of Oklahoma Health Sciences Center (OUHSC) and additional analysis conducted by the Center for Oversight and Enforcement (COE), the U.S. Public Health Service (PHS) found that Ms. Joy Bryant, Tribal Epidemiologist, OUHSC, engaged in scientific misconduct in research supported by National Institutes of Health (NIH), National Institutes of Health (NIH), grant R01 ES008755.

Specifically, Ms. Bryant falsified research in the TEAL study by substituting or conspiring with another phlebotomist for blood samples of 10-15 child participants in 1998.


Ms. Bryant has entered into a Voluntary Exclusion Agreement (Agreement) in which she has agreed to be excluded for three (3) years, beginning on May 30, 2007:

- (1) To exclude herself from any contracting or subcontracting with any agency of the United States Government or involvement in nonprocurement programs of the United States Government as defined in the Federal Acquisition Regulation (FAR) and the Federal Acquisition Regulation (FAR) Guidelines to Agencies on Governmentwide Debarment and Suspension at 2 CFR part 376
- (2) to exclude herself from serving in any advisory capacity to PHS, including but not limited to committee, board, and/or peer review committee, or as a consultant.

FOR FURTHER INFORMATION CONTACT:

Director, Division of Investigative Oversight
Office of Research Integrity
1101 Wootton Parkway, Suite 750,
Rockville, MD 20852
(240) 453-8800

John Dahlberg
Acting Director
Office of Research Integrity



New CGS publication
identifies best practices in
RCR

This page last was updated on June 26,

Legal Disclaimer / Accessibility



U.S. Department of Health and Human Services
Office of Research Integrity • 1101 Wootton Parkway • Suite 750 • Rockvil
Directions to ORI Office
Questions/suggestions about this web page? Contact the Webm





Office of Research Integrity

US Department of Health and Human Services

— HOME — ABOUT ORI — PRIVACY — FOIA — SITE MAP — CONTACT ORI —


Search ORI

Sections

- Assurance
- Conferences
- Handling Misconduct
- International
- Policies / Regulations
- Publications
- RCR Education
- Research
- RIOs

Newsletter


Latest Newsletter (PDF)
June 2007



Past Issues...

Annual Report

ORI Annual Report 2006
PDF format



Past Reports...

Graduate RCR

Graduate Education for RCR

Case Summary - James David Lieber

[Federal Register: July 23, 2007 (Volume 72, Number 140)]

[Notices]

[Page 40157]

From the Federal Register Online via GPO Access

[wais.access.gpo.gov] [DOCID:fr23jy07-55]

DEPARTMENT OF HEALTH AND HUMAN SERVICES
Office of the Secretary

Findings of Research Misconduct

ACTION: Notice.

SUMMARY: Notice is hereby given that the Office of Research Integrity (ORI) and the Assistant Secretary for Health Policy and Law (ASHP) have taken final action in the following case:


James David Lieber, University of California at Los Angeles: Based on the findings of an investigation conducted by the Office of Research Integrity (ORI) and the Assistant Secretary for Health Policy and Law (ASHP) at the University of California at Los Angeles (UCLA) and additional analysis and information obtained by the ORI during its oversight review, the U.S. Public Health Service (PHS) found that James David Lieber, M.D., Institute for Neuroscience and Human Behavior, Integrated Substance Abuse Programs, University of California at Los Angeles, was engaged in research funded by National Institute on Drug Abuse (NIDA), National Institutes of Health

Mr. Lieber knowingly and intentionally falsified and fabricated multiple follow-up interviews, records of human subject study participants and entered such false and fabricated data into the study database. Follow-up interviews of opiate users were planned to be completed as part of a study of geriatric opiate users in California. Mr. Lieber was assigned to interview 53 of the 132 subjects located for the study. Mr. Lieber falsely claimed to have conducted face-to-face interviews for the study with 20 of the subjects. A review by the ORI revealed that Mr. Lieber fabricated interviews for 20 of the 53 interviews assigned to him. In addition, he falsified the study database and caused the entry of false information into the study tracking and locating data base for 20 of the subjects. Mr. Lieber also included the theft of \$5180 for incentive payments to subjects and travel expenses.

ORI has implemented the following administrative actions for a period of three (3) years, beginning on the date of the final action:

- (1) Mr. Lieber is debarred from eligibility for any contracting or subcontracting with any agency and from eligibility or involvement in nonprocurement programs of the United States Government transactions" as defined in HHS' implementation of OMB Guidelines to Agencies on Government Procurement at 2 CFR part 376, et seq.; and
- (2) Mr. Lieber is prohibited from serving in any advisory capacity to PHS, including but not limited to a committee, board, and/or peer review committee, or as a consultant.

FOR FURTHER INFORMATION CONTACT:
Director, Division of Investigative Oversight



Office of Research Integrity
1101 Wootton Parkway, Suite 750,
Rockville, MD 20852
(240) 453-8800

Chris B. Pascal
Director
Office of Research Integrity

New CGS publication
identifies best practices in
RCR

This page last was updated on July 26,

Legal Disclaimer / Accessibility



U.S. Department of Health and Human Services
Office of Research Integrity • 1101 Wootton Parkway • Suite 750 • Rockvil
Directions to ORI Office
Questions/suggestions about this web page? Contact the Webm

